[1]陈珉惺,唐 密,杨 燕,等.国家药品集中带量采购中标结果及中标企业规模分析[J].卫生经济研究,2025,42(05):78-80,84.
　CHEN Minxing,TANG Mi,YANG Yan,et al.Analysis of Bidding Results and Enterprise Scales in National Centralized Volume-based Procurement of Drugs[J].Journal Press of Health Economics Research,2025,42(05):78-80,84.
点击复制

国家药品集中带量采购中标结果及中标企业规模分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
42
期数:
2025年05期
页码:
78-80,84
栏目:
药械管理
出版日期:
2025-04-24

文章信息/Info

Title:
Analysis of Bidding Results and Enterprise Scales in National Centralized Volume-based Procurement of Drugs
作者:
陈珉惺1; 唐 密1; 杨 燕1; 吴卿仪1; 冯旅帆1; 金春林1
1.上海市卫生和健康发展研究中心（上海市医学科学技术情报研究所），上海 200031
Author(s):
CHEN Minxing;  TANG Mi;  YANG Yan;  WU Qingyi;  FENG Lyufan;  JIN Chunlin
Shanghai Health Development Research Center (Shanghai Medical Information Center), Shanghai 200031, China
关键词:
国家药品集中带量采购; 中标结果; 企业规模
Keywords:
national centralized volume-based procurement of drugs;  bidding results;  enterprise scale
分类号:
R95
文献标志码:
A
摘要:
目的：分析九批十轮国家药品集中带量采购中标结果及中标企业规模，为国家药品集中带量采购制度化推进和医药产业可持续发展提供参考依据。方法：采用描述性分析法和关键知情人访谈法，基于官方数据进行定量定性分析。结果：九批十轮国家药品集中带量采购中，中选品种数、采购金额总体呈上升趋势，药品和企业中标率趋于平稳，中标药品价格平均降幅稳定在50%左右；中标企业规模分析显示，头部与尾部企业中标率呈现“U型”分布，未出现尾部企业以极低价中标的现象。结论：国家药品集中带量采购对药品市场影响深远，中小企业以极低价竞争入局的现象得以遏制，仍需持续发挥政策倒逼企业创新的作用。
Abstract:
Objective To analyze the bidding results and enterprise scales in nine batches and ten rounds of national centralized volume-based procurement of drugs, and to provide reference evidences for the institutional advancement of national centralized volume-based procurement of drugs and the sustainable development of the pharmaceutical industry. Methods Descriptive analysis and key informant interviews were conducted. Based on official data from the National Healthcare Security Administration and the "China Pharmaceutical Statistics Annual Report" from 2017 to 2022 by the Ministry of Industry and Information Technology, both quantitative and qualitative analysis were performed. Results Across the nine batches and ten rounds of national centralized volume-based procurement of drugs, the number of selected drug varieties and procurement volumes generally showed an upward trend. The bidding success rates for both drugs and enterprises tended to stabilize, and the average price reduction of the successful bidding drugs stabilized at approximately 50%. Analysis of the scales of successful bidding enterprises revealed a "U-shaped" distribution in bidding success rates among both top and tail enterprises, and the phenomenon of tail enterprises winning the bidding at extremely low prices did not occur. Conclusion National centralized volume-based procurement of drugs has a profound impact on the pharmaceutical market. The phenomenon of small and medium-sized enterprises competing at extremely low prices has been curbed. It is necessary to continue to play the role of the policy to force enterprises to innovate.

参考文献/References:

[1] 赵静.药品集中带量采购对医药行业的影响研究 [J].中国价格监管与反垄断，2024（02）：31-33.
[2] 张秋玉，禄晓龙，王芸，等.药品集中带量采购政策对我国医药制造业上市企业创新绩效的影响[J].医学与社会，2022，35（12）：17-23.
[3] 陈珉惺，徐源，何江江，等.国家药品集中采购中标企业规模结构分析及启示[J].中国卫生经济，2022，41（04）：67-69.
[4] 杜雪，马珺，黎雯霞.药品带量采购存在的问题与对策分析[J].卫生经济研究，2020，37（08）：42-44，49.
[5] 马科妮.国家药品集采价格降幅影响因素分析——基于Logistic回归模型[J].中国医疗保险，2024（05）：116-121.
[6] Wang J,Yang Y,Xu L,et al.Impact of “4+7”volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China[J].BMJ Open,2022,12(03):e0554346.
[7] 李钊，陈盛，周绿林，等.国家组织药品集中带量采购的实践操作问题与优化对策[J].中国卫生经济，2022，41（07）：60-64.
[8] 黎东生，白雪珊.带量采购降低药品价格的一般机理及“4+7招采模式”分析[J].卫生经济研究，2019，36（08）：10-12.
[9] 顾灵娜，蒋茜，路云，等.博弈论视角下药品集中带量采购激励约束机制研究[J].医学与社会，2023，36（12）：138-144.
[10] 谢金平，张雪瑞，张赫，等.国家药品集中采购政策的主要利益相关者分析[J].中国药房，2021，32（21）：2677-2682.
[11] 杨莹，刘雨欣，毛靖，等.药品集中带量采购政策对我国医药产业的影响——基于SCP范式的综述研究[J].中国卫生政策研究，2023，16（12）：40-48.

更新日期/Last Update: 2025-04-24